154 related articles for article (PubMed ID: 33483290)
21. Association between quality of life and clinical parameters in patients with myeloproliferative neoplasms.
Johansson P; Mesa R; Scherber R; Abelsson J; Samuelsson J; Birgegård G; Andréasson B
Leuk Lymphoma; 2012 Mar; 53(3):441-4. PubMed ID: 21883029
[TBL] [Abstract][Full Text] [Related]
22. Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy.
Mesa R; Verstovsek S; Kiladjian JJ; Griesshammer M; Masszi T; Durrant S; Passamonti F; Harrison CN; Pane F; Zachee P; Zhen H; Jones MM; Parasuraman S; Li J; Côté I; Habr D; Vannucchi AM
Eur J Haematol; 2016 Aug; 97(2):192-200. PubMed ID: 26608702
[TBL] [Abstract][Full Text] [Related]
23. Clinical characteristics and symptom burden of Thai myeloproliferative neoplasm patients.
Cherdchoo N; Polprasert C; Rojnuckarin P; Kongkiatkamon S
Hematology; 2023 Dec; 28(1):2280731. PubMed ID: 37942783
[No Abstract] [Full Text] [Related]
24. Symptom Burden and Blood Counts in Patients With Polycythemia Vera in the United States: An Analysis From the REVEAL Study.
Grunwald MR; Burke JM; Kuter DJ; Gerds AT; Stein B; Walshauser MA; Parasuraman S; Colucci P; Paranagama D; Savona MR; Mesa R
Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):579-584.e1. PubMed ID: 31303457
[TBL] [Abstract][Full Text] [Related]
25. The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey.
Harrison CN; Koschmieder S; Foltz L; Guglielmelli P; Flindt T; Koehler M; Mathias J; Komatsu N; Boothroyd RN; Spierer A; Perez Ronco J; Taylor-Stokes G; Waller J; Mesa RA
Ann Hematol; 2017 Oct; 96(10):1653-1665. PubMed ID: 28780729
[TBL] [Abstract][Full Text] [Related]
26. Depressive symptoms and myeloproliferative neoplasms: Understanding the confounding factor in a complex condition.
Padrnos L; Scherber R; Geyer H; Langlais BT; Dueck AC; Kosiorek HE; Senyak Z; Clark M; Boxer M; Cotter M; Harrison C; Stonnington C; Geda Y; Mesa R
Cancer Med; 2020 Nov; 9(22):8301-8309. PubMed ID: 32976697
[TBL] [Abstract][Full Text] [Related]
27. Brazilian-Portuguese validation of the University of Washington Quality of Life Questionnaire for patients with head and neck cancer.
Vartanian JG; Carvalho AL; Yueh B; Furia CL; Toyota J; McDowell JA; Weymuller EA; Kowalski LP
Head Neck; 2006 Dec; 28(12):1115-21. PubMed ID: 16823873
[TBL] [Abstract][Full Text] [Related]
28. The Vanderbilt Head and Neck Symptom Survey Brazilian Portuguese version 2.0 (VHNSS 2.0): psychometric properties for patients with head and neck cancer who have undergone radiotherapy.
Barroso EM; Carvalho AL; Paiva CE; Murphy BA; Paiva BS
BMC Res Notes; 2015 Oct; 8():522. PubMed ID: 26428472
[TBL] [Abstract][Full Text] [Related]
29. Translation into Portuguese, cross-cultural adaptation and validation of "The European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire-Bone Metastases-22".
Miki-Rosário N; Garcia Filho RJ; Garcia JG; Dini GM; Bottomley A; Chow E; Sabino Neto M
Ann Palliat Med; 2016 Jul; 5(3):190-5. PubMed ID: 27334351
[TBL] [Abstract][Full Text] [Related]
30. Body Mass Index and Total Symptom Burden in Myeloproliferative Neoplasms Discovery of a U-shaped Association.
Christensen SF; Scherber RM; Brochmann N; Goros M; Gelfond J; Andersen CL; Flachs EM; Mesa R
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32781663
[TBL] [Abstract][Full Text] [Related]
31. Translation and psychometric validity of the Brazilian version of the European Organisation for Research and Treatment of Cancer-colorectal liver metastases module.
Tomim DH; Lenhani BE; de Alcântara Nogueira L; Vogt TN; Dos Santos Silva L; de Fátima Mantovani M; Guimarães PRB; Kalinke LP
Ecancermedicalscience; 2022; 16():1346. PubMed ID: 35242227
[TBL] [Abstract][Full Text] [Related]
32. Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group.
Geyer HL; Kosiorek H; Dueck AC; Scherber R; Slot S; Zweegman S; Te Boekhorst PA; Senyak Z; Schouten HC; Sackmann F; Fuentes AK; Hernández-Maraver D; Pahl HL; Griesshammer M; Stegelmann F; Döhner K; Lehmann T; Bonatz K; Reiter A; Boyer F; Etienne G; Ianotto JC; Ranta D; Roy L; Cahn JY; Harrison CN; Radia D; Muxi P; Maldonado N; Besses C; Cervantes F; Johansson PL; Barbui T; Barosi G; Vannucchi AM; Paoli C; Passamonti F; Andreasson B; Ferrari ML; Rambaldi A; Samuelsson J; Cannon K; Birgegard G; Xiao Z; Xu Z; Zhang Y; Sun X; Xu J; Kiladjian JJ; Zhang P; Gale RP; Mesa RA
Haematologica; 2017 Jan; 102(1):85-93. PubMed ID: 27540137
[TBL] [Abstract][Full Text] [Related]
33. The SIMM study: Survey of integrative medicine in myeloproliferative neoplasms.
Gowin K; Langlais BT; Kosiorek HE; Dueck A; Millstine D; Huberty J; Eckert R; Mesa RA
Cancer Med; 2020 Dec; 9(24):9445-9453. PubMed ID: 33140580
[TBL] [Abstract][Full Text] [Related]
34. Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey.
Mesa RA; Miller CB; Thyne M; Mangan J; Goldberger S; Fazal S; Ma X; Wilson W; Paranagama DC; Dubinski DG; Naim A; Parasuraman S; Boyle J; Mascarenhas JO
Cancer; 2017 Feb; 123(3):449-458. PubMed ID: 27690182
[TBL] [Abstract][Full Text] [Related]
35. Assessing the acceptability, reliability, and validity of the EORTC Quality of Life Questionnaire (QLQ-C30) in Kenyan cancer patients: a cross-sectional study.
Davda J; Kibet H; Achieng E; Atundo L; Komen T
J Patient Rep Outcomes; 2021 Jan; 5(1):4. PubMed ID: 33415528
[TBL] [Abstract][Full Text] [Related]
36. Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey.
Mesa R; Miller CB; Thyne M; Mangan J; Goldberger S; Fazal S; Ma X; Wilson W; Paranagama DC; Dubinski DG; Boyle J; Mascarenhas JO
BMC Cancer; 2016 Feb; 16():167. PubMed ID: 26922064
[TBL] [Abstract][Full Text] [Related]
37. Translation and Validation of the Arrhythmia-Specific Questionnaire in Tachycardia and Arrhythmia (ASTA) to the Brazilian Context: An Instrument Focusing on Arrhythmia Symptoms.
Cannavan PMS; Cannavan FPS; Walfridsson U; Lopes MHBM
Cardiol Res Pract; 2020; 2020():1402916. PubMed ID: 32351731
[TBL] [Abstract][Full Text] [Related]
38. Psychometric evaluation of the Advanced Systemic Mastocytosis Symptom Assessment Form (AdvSM-SAF).
Taylor F; Li X; Yip C; Padilla B; Mar B; Green T; Oren R; Boral AL; Lin HM; Shields AL; Gotlib J
Leuk Res; 2021 Sep; 108():106606. PubMed ID: 34004551
[TBL] [Abstract][Full Text] [Related]
39. Psychometric evaluation of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF
Shields AL; Taylor F; Lamoureux RE; Padilla B; Severson K; Green T; Boral AL; Akin C; Siebenhaar F; Mar B
Orphanet J Rare Dis; 2023 Mar; 18(1):69. PubMed ID: 36964624
[TBL] [Abstract][Full Text] [Related]
40. Psychometric properties of the updated EORTC module for assessing quality of life in patients with lung cancer (QLQ-LC29): an international, observational field study.
Koller M; Shamieh O; Hjermstad MJ; Hornslien K; Young T; Chalk T; Ioannidis G; Harle A; Johnson CD; Tomaszewski KA; Serpentini S; Pinto M; van der Weijst L; Janssens A; Morag O; Chie WC; Arraras JI; Pompili C; Jungraithmayr W; Hechtner M; Katsochi D; Müller K; Gräfenstein L; Schulz C; Bottomley A; ; ;
Lancet Oncol; 2020 May; 21(5):723-732. PubMed ID: 32213338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
